<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524120</url>
  </required_header>
  <id_info>
    <org_study_id>HN-0009</org_study_id>
    <nct_id>NCT01524120</nct_id>
  </id_info>
  <brief_title>Endoscopy and Endomicroscopy for Assessment of Mucosal Healing in Inflammatory Bowel Disease (IBD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel disease (IBD) encompasses two major forms of chronic intestinal disorders,&#xD;
      Crohn's disease and ulcerative colitis (UC). Diagnosis is based on several macroscopic and&#xD;
      histologic features including patterns of inflammation, crypt abscesses and granulomas.&#xD;
      Confocal laser endomicroscopy (CLE) is rapidly emerging as a valuable tool for&#xD;
      gastrointestinal endoscopic imaging, enabling the endoscopist to obtain an &quot;optical biopsy&quot;&#xD;
      of the gastrointestinal mucosa during the endoscopic procedure.&#xD;
&#xD;
      The main objective of this study is to determine endoscopic and endomicroscopic features of&#xD;
      mucosal healing in patients with IBD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2012</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mucosal healing</measure>
    <time_frame>3 years</time_frame>
    <description>We will determine endoscopic (e.g. ulcera, erythema) and endomicroscopic features of mucosal inflammation (e.g. goblet cell depletion, leackage, microvessel density) in IBD in order to define new criteria of mucosal healing and to define factors of disease remission and relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic correlation</measure>
    <time_frame>3 years</time_frame>
    <description>Comparison of clinical and histopathological data with endoscopic and endomicroscopic findings to evaluate mucosal healing as a parameter of remission and relapse in patients with IBD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic effect</measure>
    <time_frame>3 years</time_frame>
    <description>We will evaluate the effect of different therapeutic strategies (eg. anti-TNF treatment, corticosteroids) on characteristics of mucosal healing (e.g. goblet cell depletion, microvessels, leakage) and remission and relapse rate.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Crohn's disease (CD)</arm_group_label>
    <description>Patients with CD and mucosal healing on endoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <description>Patients with CD and mucosal healing on endomicroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis (UC)</arm_group_label>
    <description>Patients with UC and mucosal healing on endoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis</arm_group_label>
    <description>Patients with UC and mucosal healing on endomicroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopy (EPK-i, Pentax, Tokyo, Japan)</intervention_name>
    <description>Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.</description>
    <arm_group_label>Crohn's disease (CD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endomicroscopy (iCLE, Pentax, Tokyo, Japan)</intervention_name>
    <description>Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.</description>
    <arm_group_label>Crohn's disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopy (EPK-i, Pentax, Tokyo, Japan)</intervention_name>
    <description>Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.</description>
    <arm_group_label>Ulcerative colitis (UC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endomicroscopy (iCLE, Pentax, Tokyo, Japan)</intervention_name>
    <description>Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.</description>
    <arm_group_label>Ulcerative colitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsies were taken from every patient for subsequent histological analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Crohn´s disease and ulcerative colitis. Only patients with mucosal healing&#xD;
        are included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  Ability of subjects to understand character and individual consequences of clinical&#xD;
             trial&#xD;
&#xD;
          -  Subjects undergoing colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Severe Coagulopathy (Prothrombin time &lt; 50% of control, Partial thromboplastin time &gt;&#xD;
             50 s)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Active gastrointestinal bleeding&#xD;
&#xD;
          -  Residing in institutions (e.g. prison)&#xD;
&#xD;
          -  Known allergy against fluorescein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus F. Neurath, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nürnberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Neumann, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nürnberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Erlangen-Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>January 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucosal healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

